Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828009 · ClinicalTrials.gov registry record · Phase 2
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
A Phase 2 study of Lung Cancer, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT00828009 is a Phase 2 study of Lung Cancer that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 70 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00828009, a Phase 2 study of Lung Cancer, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine therapy together with bevacizumab after chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving BLP25 liposome vaccine together with bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG paclitaxel
- BIOLOGICAL bevacizumab
- BIOLOGICAL Tecemotide
Study Locations (20)
Illinois
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- Hematology and Oncology Associates - Chicago
- Saint Joseph Hospital - Chicago
- Decatur Memorial Hospital Cancer Care Institute - Decatur
- Eureka Community Hospital - Eureka
- Galesburg Clinic, PC - Galesburg
- Ingalls Cancer Care Center at Ingalls Memorial Hospital - Harvey
- Mason District Hospital - Havana
- Kellogg Cancer Care Center - Highland Park
- Hinsdale Hematology Oncology Associates - Hinsdale
- Provena St. Mary's Regional Cancer Center - Kankakee - Kankakee
- North Shore Oncology and Hematology Associates, Limited - Libertyville - Libertyville
- McDonough District Hospital - Macomb
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus - Moline
California
- Veterans Affairs Medical Center - Palo Alto - Palo Alto
- Stanford Cancer Center - Stanford
Georgia
- Medical Center of Central Georgia - Macon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-01-17 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00828009
The ClinicalTrials.gov registry entry for NCT00828009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which carboplatin is the first listed.
NCT00828009 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Illinois, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT00828009 about?
NCT00828009 is a clinical study titled "BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery". RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-kill...
What is the current status of trial NCT00828009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2011-01-17. Estimated completion is 2019-05-22.
What conditions does trial NCT00828009 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00828009?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), paclitaxel (DRUG), bevacizumab (BIOLOGICAL), Tecemotide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00828009?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00828009 being conducted?
This trial has 20 study locations across California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.